%A SHAO Lan %T Treatment of recurrent small cell lung cancer %0 Journal Article %D 2012 %J Journal of International Oncology %R %P 373-376 %V 39 %N 5 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_8788.shtml} %8 2012-05-08 %X Smallcell lung cancer (SCLC) relapses in the majority of patients, even though most patients respond to firstline therapy. Subsequent therapy can provide significant palliation and prolongation of survival for many patients. At present, topotecan is considered the standard secondline chemotherapy. Recently, amrubicin has also shown more favorable antitumor activity, and is the most promising at present. Unfortunately, targeted agents have failed to demonstrate effectiveness for SCLC.